Opinion|Videos|January 24, 2024
Supportive Care and Managing Toxicities Related to ADCs in TNBC
A panel of medical oncologists provides insights on managing toxicities in patients with triple-negative breast cancer who are receiving antibody-drug conjugates.
Advertisement
Advertisement
Related to this article
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer.
ASCENT-03 subgroup data show sacituzumab govitecan improved PFS vs chemotherapy across subgroups in untreated metastatic TNBC.
KEYNOTE-B49 data show pembrolizumab plus chemotherapy improved PFS but not OS in PD-L1–positive HR+/HER2– advanced breast cancer.
At Big Ten CRC, Patricia A. Robinson, MD, discussed institutional and cooperative group strategies that have improved representation in oncology clinical trials.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
3
EU Approves T-DXd for HER2+ Early Breast Cancer With Residual Disease
4
Better Biomarkers Needed to Guide Neoadjuvant Chemoimmunotherapy in NSCLC
5